Process of making and using pharmaceutical formulations of antineoplastic agents

ABSTRACT

In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.

This application is a divisional application of U.S. Ser. No. 10/371,808filed Feb. 21, 2003, now allowed, which claims the benefit of U.S. Ser.No. 60/359,198 filed Feb. 22, 2002, the entirety of which areincorporated by reference as if set forth fully herein.

FIELD OF THE INVENTION

The present invention pertains to pharmaceutical formulations comprisingantineoplastic agents, such as Temozolomide, and dissolution enhancingagents.

BACKGROUND OF INVENTION

Antineoplastic agents are useful in cancer therapies against a widearray of cancer and other diseases. Temozolomide is one suchantineoplastic agent. U.S. Pat. No. 6,096,759 lists a variety ofantineoplastic agents including Temozolomide, the disclosure of which isincorporated herein by reference.

Temozolomide is known for its anti-tumor effects. For example, one studyshowed that clinical responses were achieved in 17% of patients havingadvanced melanoma (Newlands E S, et al. Br J Cancer 65 (2) 287-2981(1992)). In another study, a clinical response was achieved in 21% ofpatients with advanced melanoma (Journal of Clinical Oncology, 13(4)910-913 (1995)). Treatment of gliomas in adults with Temozolomide isalso known (Eur. J. Cancer 29A 940 (1993)). Treatment of the followingcancers in adults with Temozolomide has also been disclosed: metastaticmelanoma; malignant melanoma, high grade glioma, glioblastoma and otherbrain cancers; lung cancer; breast cancer; testicular cancer; colon andrectal cancers; carcinomas; sarcomas; lymphomas; leukemias; anaplasticastrocytoma; and mycosis fungoides.

Temozolomide is a water-insoluble compound. Temozolomide has beenadministered in patients as micronized suspensions, as disclosed in U.S.Pat. No. 6,251,886. However, suspension formulations are not desirablebecause they may lead to clogged veins.

Storage of pharmaceutical and biological agents, especiallyantineoplastic agents, as a frozen solution can cause the activeingredient therein to rapidly deteriorate.

Lyophilization, also known as freeze-drying, is a process whereby wateris sublimed from a composition after it is frozen. In this process,pharmaceutical and biological agents that are relatively unstable in anaqueous solution over a period of time can be placed into dosagecontainers in an easily processed liquid state, dried without the use ofdamaging heat and stored in a dried state for extended periods. Mostpharmaceutical and biological agents, including antineoplastic agents,require additional ingredients to protect the active ingredient duringlyophilization. In addition, it can be difficult to reconstitute alyophilized antineoplastic agent into an aqueous solution.

Accordingly there is an increased need for formulations containingantineoplastic agents, such as Temozolomide, which are water soluble,stable and/or suitable for lyophilization, long term storage andreconstitution of the lyophilized formulation into an aqueous solution.

Furthermore, there is an increased need for administering to a patientan antineoplastic agent, such as Temozolomide, as a water soluble andstable formulation.

SUMMARY OF THE INVENTION

This invention relates to pharmaceutical formulations comprising atleast one antineoplastic agent, processes of making the same, processesof lyophilization of the pharmaceutical formulations, lyophilizedpowders and articles of manufacture thereof, pharmaceutical formulationscomprising the lyophilized powder reconstituted in at least one aqueousdiluent, and processes of treating or preventing diseases comprisingadministering the pharmaceutical formulation to an animal in needthereof.

One aspect of the invention relates to a pharmaceutical formulationcomprising at least one antineoplastic agent or a pharmaceuticallyacceptable salt thereof, at least one aqueous diluent, and at least onedissolution enhancing agent sufficient to substantially dissolve saidantineoplastic agent(s), wherein said dissolution enhancing agent isurea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine ormixtures thereof.

Another aspect of the invention relates to a process for making thepharmaceutical formulation of the invention. This process comprises thesteps of dissolving at least one dissolution enhancing agent in at leastone aqueous diluent, and adding at least one antineoplastic agent or apharmaceutically acceptable salt thereof.

Another aspect of the invention relates to a lyophilized powder producedby lyophilization of the pharmaceutical formulation of the invention.

Another aspect of the invention relates to an article of manufacturecomprising a container containing the lyophilized powder of theinvention.

Another aspect of the invention relates to a pharmaceutical formulationsuitable for administration to a patient, wherein the formulation isprepared by reconstituting (resolubilizing) the lyophilized powder ofthe invention in a volume of water or other aqueous diluent.

Another aspect of the invention relates to a process for treating orpreventing diseases in patients comprising administering atherapeutically effective amount of the pharmaceutical formulation ofthe invention to a patient in need thereof.

Other aspects of this invention relate to and disclose pharmaceuticalformulations of Temozolomide, a process of making the same, alyophilized powder of said formulation and articles of manufacturethereof, a pharmaceutical formulation comprising the lyophilized powderreconstituted in water or other aqueous diluents, and a process oftreating or preventing diseases (such as, for example, cancer)comprising administering the pharmaceutical formulation to a patient inneed thereof.

DETAILED DESCRIPTION

The pharmaceutical formulation of the invention comprises at least oneantineoplastic agent or a pharmaceutically acceptable salt thereof, atleast one aqueous diluent, and at least one dissolution enhancing agentsufficient to substantially dissolve the antineoplastic agent in theaqueous diluent(s). The percentage of the antineoplastic agent which isdissolved in the pharmaceutical formulation can range from about 50% toabout 100%, preferably from about 75% to about 100%, and more preferablyabout 100%.

The dissolution enhancing agent is urea, L-histidine, L-threonine,L-asparagine, L-serine, L-glutamine or mixtures thereof. The dissolutionenhancing agent increases the rate in which the antineoplastic agentdissolves in the aqueous diluent(s). The time to it takes to completedissolution of at least one antineoplastic agent with a dissolutionagent in at least one aqueous diluent in a 25 mg vial can range fromabout 30 seconds to about 90 seconds, preferably from about 30 secondsto about 60 seconds, more preferably about 30 seconds.

When urea is used in the pharmaceutical formulation as the dissolutionenhancing agent, its weight percent (wt %) in the pharmaceuticalformulation can range from about 4 wt % to about 60 wt %, preferablyfrom about 8 wt % to about 30 wt %, more preferably from about 12 wt %to about 22 wt %.

When L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine ormixtures thereof are used in the pharmaceutical formulation as thedissolution enhancing agent(s), its wt % in the pharmaceuticalformulation can range from about 2 wt % to about 60 wt %, preferablyfrom about 4 wt % to about 40 wt %, more preferably from about 8 wt % toabout 20 wt %.

When L-histidine is the only amino acid used in the pharmaceuticalformulation as the dissolution enhancing agent, its wt % in thepharmaceutical formulation can range preferably from about 1 wt % toabout 30 wt %, more preferably from about 2 wt % to about 20 wt %, andmost preferably from about 4 wt % to about 10 wt %.

Non-limiting examples of useful antineoplastic agents includeTemozolomide (commercially available under the trademark TEMODAR® fromSchering-Plough Corporation, Kenilworth, N.J.), Uracil Mustard,Chlormethine, Cyclophosphamide, Ifosfamide, Melphalan, Chlorambucil,Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan,Carmustine, Lomustine, Streptozocin, Dacarbazine, Methotrexate,5-Fluorouracil, Floxuridine, Cytarabine, 6-Mercaptopurine,6-Thioguanine, Fludarabine phosphate, Pentostatine, Gemcitabine,Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin,Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Paclitaxel,Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Interferons,Etoposide, Teniposide 17.alpha.-Ethinylestradiol, Diethylstilbestrol,Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate,Testolactone, Megestrolacetate, Tamoxifen, Methylprednisolone,Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene,Hydroxyprogesterone, Aminoglutethimide, Estramustine,Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene,Goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine,Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole,Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, and mixturesthereof.

In a preferred embodiment, at least one of the antineoplastic agents isTemozolomide.

In another preferred embodiment, the antineoplastic agent is atherapeutically effective amount of Temozolomide.

The wt % of the antineoplastic agent in the pharmaceutical formulationcan range from about 1 wt % to about 50 wt %, preferably from about 2 wt% to about 30 wt %, more preferably from about 4 wt % to about 16 wt %.

In another embodiment, the pharmaceutical formulation further comprisesat least one excipient. Non-limiting examples of suitable excipientsinclude polysorbates, polyethylene glycols (PEG), propylene glycols,polysorbates or suitable mixtures thereof. The excipient is used toincrease the solubility of the antineoplastic agent.

The average molecular weight of polysorbates can range from about 500g/mole to about 1900 g/mole, preferably from about 800 g/mole to about1600 g/mole, more preferably from about 1000 g/mole to about 1400g/mole. Non-limiting examples of polysorbates include polysorbate 20,polysorbate 21, polysorbate 40, polysorbate 60, polysorbate 61,polysorbate 65, polysorbate 81, polysorbate 85, and polysorbate 120.Preferred polysorbates include polysorbate 20, polysorbate 80, andmixtures thereof.

The average molecular weight of PEG can range from about 200 g/mole toabout 600 g/mole, preferably from about 200 g/mole to about 500 g/mole,more preferably from about 200 g/mole to about 400 g/mole. Non-limitingexamples include PEG 200, PEG 300, PEG 400, PEG 540, and PEG 600.

Propylene glycol is a small molecule with a molecular weight of about76.1 g/mole.

When an excipient is used in the pharmaceutical formulation, its wt % inthe pharmaceutical formulation can range from about 1 wt % to about 50wt %, preferably from about 2 wt % to about 30 wt %, more preferablyfrom about 4 wt % to about 16 wt %.

In another embodiment, the pharmaceutical formulation further comprisesat least one bulking agent. Non-limiting examples of suitable bulkingagents which can be included in the pharmaceutical formulation includemannitol, lactose, sucrose, sodium chloride, trehalose, dextrose,starch, hydroxyethylstarch (hetastarch), cellulose, cyclodextrins,glycine, or mixtures thereof.

In a preferred embodiment, the bulking agent in the pharmaceuticalformulation is mannitol.

When a bulking agent is used in the pharmaceutical formulation, its wt %in the pharmaceutical formulation can range from about 20 wt % to about80 wt %, preferably from about 35 wt % to about 65 wt %, more preferablyfrom about 40 wt % to about 56 wt %.

In another embodiment, the pharmaceutical formulation further comprisesat least one buffer.

Non-limiting examples of suitable buffers which can be included in thepharmaceutical formulation include citrate buffers, lithium lactate,sodium lactate, potassium lactate, calcium lactate, lithium phosphate,sodium phosphate, potassium phosphate, calcium phosphate, lithiummaleate, sodium maleate, potassium maleate, calcium maleate, lithiumtartarate, sodium tartarate, potassium tartarate, calcium tartarate,lithium succinate, sodium succinate, potassium succinate, calciumsuccinate, lithium acetate, sodium acetate, potassium acetate, calciumacetate, or mixtures thereof.

Preferably, a buffer used in the pharmaceutical formulation is at leastone citrate buffer. Non-limiting examples of suitable citrate buffersinclude lithium citrate monohydrate, sodium citrate monohydrate,potassium citrate monohydrate, calcium citrate monohydrate, lithiumcitrate dihydrate, sodium citrate dihydrate, potassium citratedihydrate, calcium citrate dihydrate, lithium citrate trihydrate, sodiumcitrate trihydrate, potassium citrate trihydrate, calcium citratetrihydrate, lithium citrate tetrahydrate, sodium citrate tetrahydrate,potassium citrate tetrahydrate, calcium citrate tetrahydrate, lithiumcitrate pentahydrate, sodium citrate pentahydrate, potassium citratepentahydrate, calcium citrate pentahydrate, lithium citrate hexahydrate,sodium citrate hexahydrate, potassium citrate hexahydrate, calciumcitrate hexahydrate, lithium citrate heptahydrate, sodium citrateheptahydrate, potassium citrate heptahydrate, or calcium citrateheptahydrate.

When a buffer is used in the pharmaceutical formulation, its wt % in thepharmaceutical formulation can range from about 5 wt % to about 60 wt %,preferably from about 10 wt % to about 40 wt %, more preferably fromabout 15 wt % to about 28 wt %.

In another embodiment, the pharmaceutical formulation further comprisesa pH adjuster. Non-limiting examples of suitable pH adjusters which canbe included in the pharmaceutical formulation are hydrochloric acid,sodium hydroxide, citric acid, phosphoric acid, lactic acid, tartaricacid, succinic acid, or mixtures thereof.

A preferred pH adjuster for the pharmaceutical formulation ishydrochloric acid.

When a pH adjuster is used in the pharmaceutical formulation, its wt %in the pharmaceutical formulation can range from about 1 wt % to about20 wt %, preferably from about 2 wt % to about 12 wt %, more preferablyfrom about 4 wt % to about 8 wt %.

The pH of the pharmaceutical formulation preferably ranges from about2.5 to about 6.0, more preferably from about 3.0 to about 4.5, and mostpreferably from about 3.8 to about 4.2.

The pharmaceutical formulation and the lyophilized powders thereof canbe stored in containers commonly used in the pharmaceutical industry,which can include plastic containers or glass containers such asstandard USP Type I borosilicate glass containers. For example, thecontainer used can be a syringe or vial.

Another aspect of the invention relates to a process for making thepharmaceutical formulation of the invention. This process comprises thesteps of dissolving at least one dissolution enhancing agent in at leastone aqueous diluent, and adding at least one antineoplastic agent or apharmaceutically acceptable salt thereof, preferably in that order. Inthe ideal embodiment, the antineoplastic agent is added after thedissolution enhancing agent is completely dissolved. The dissolutionenhancing agent can be urea, L-histidine, L-threonine, L-asparagine,L-serine, L-glutamine or mixtures thereof. The volume of aqueousdiluent(s) preferably comprises at least 80% of the total volume.

In another embodiment, the process further comprises adding at least onebulking agent; adding at least one buffer; and adding at least one pHadjuster to form a solution; preferably in that order, and filtering thesolution.

In another embodiment, the process further comprises filling thefiltered solution into a lyophilization container and lyophilizing thesolution contained within the lyophilization container to produce alyophilized powder. “Lyophilized powders” for purposes of this inventionis meant to include all lyophilized forms including lyophilized cakes.

The moisture content of the lyophilized powders can range from to about0.1% to about 3%, preferably from about 0.2% to about 0.8%, morepreferably from about 0.2% to about 0.6%. Moisture content can bemeasured by a moisture analyzer; many suitable moisture analyzers arecommercially available.

Lyophilization is a process whereby water is sublimed from a formulationafter it is frozen. In this process, pharmaceutical and biologicalagents that are relatively unstable in an aqueous solution over a periodof time can be placed into dosage containers in an easily processedliquid state, dried without the use of damaging heat, and stored in adried state for extended periods.

Another aspect of the invention relates to lyophilized powders producedby lyophilization of the pharmaceutical formulation of the invention.

Another aspect of the invention relates to an article of manufacturecomprising a container containing the lyophilized powder produced by thelyophilization of the pharmaceutical formulation of the invention.Suitable containers are discussed above. In a preferred embodiment, thearticle of manufacture contains a therapeutically effective amount ofthe antineoplastic agent(s) in a lyophilized powder.

In another embodiment, the article of manufacture further comprises avolume of at least one aqueous diluent for reconstitution of thelyophilized powder. Reconstitution time generally takes from about 30seconds to about 60 seconds.

Another aspect of the invention relates to a pharmaceutical formulationsuitable for administration to a patient, said formulation prepared byreconstituting (resolubilizing) the lyophilized powder of the inventionin a volume of at least one aqueous diluent.

The lyophilized formulations of the pharmaceutical formulations can bediluted or reconstituted prior to administration with a suitable aqueousdiluent(s) to obtain a finished concentration. For example, aconcentration of from about 0.5 mg/ml to about 5 mg/ml, preferably fromabout 1 mg/ml to about 3 mg/ml, and more preferably from about 2 mg/mlto about 3 mg/ml is suitable for transfer to an infusion bag for use bya patient in need of an antineoplastic agent such as Temozolomide.

Another aspect of the invention relates to a process for treating orpreventing disease in a patient comprising administering atherapeutically effective amount of the pharmaceutical formulation ofthe invention to a patient in need thereof. The pharmaceuticalformulation in this aspect of the invention can be a formulation whichare the lyophilized powders reconstituted with water or other aqueousdiluents, or the formulations which are not prepared by reconstitutingthe lyophilized powders. Non-limiting examples of diseases which can betreated or prevented include carcinoma, sarcoma, melanoma, glioma,glioblastoma, brain cancer, lung cancer, thyroid follicular cancer,pancreatic cancer, breast cancer, anaplastic astrocytoma, bladdercancer, myelodysplasia, prostate cancer, testicular cancer, colon andrectal cancer, lymphoma, leukemia, or mycosis fungoides.

The dosage regimen utilizing the pharmaceutical formulations of theinvention is selected based upon consideration of a variety of factors,including species, age, weight, sex and medical condition of thepatient; the specific disease to be treated, the severity of thecondition to be treated; the route of administration; the renal andhepatic function of the patient; and the particular active ingredient orsalt thereof employed. An ordinarily skilled physician can readilydetermine and prescribe the effective amount of antineoplastic agentrequired to prevent, counter, or arrest the progress of the diseasecondition. For example, the adult dosage of temozolomide for an adult isgenerally about 150 mg/m² of body surface area.

The pharmaceutical formulation of the invention can be used for treatingor preventing one or more diseases such as carcinoma, sarcoma, melanoma,glioma, glioblastoma, brain cancer, lung cancer, thyroid follicularcancer, pancreatic cancer, breast cancer, bladder cancer,myelodysplasia, anaplastic astrocytoma, prostate cancer, testicularcancer, anaplastic astrocytoma, colon and rectal cancer, lymphoma,leukemia, and mycosis fungoides.

The pharmaceutical formulation, its lyophilized powder, and thepharmaceutical formulation formed by reconstituting the lyophilizedpowder with at least one aqueous diluent can provide enhanced chemicalstability. Enhanced chemical stability of the pharmaceutical formulationmeans the pharmaceutical formulation is stable in solution for at least60 hours at room temperature (about 25° C.) and ambient lightconditions. Enhanced chemical stability of the lyophilized powder meansthe lyophilized powder is suitable for storage from about 4° C. to about40° C. preferably for about 12 months or more. Enhanced chemicalstability of the pharmaceutical formulation formed by reconstituting thelyophilized powder with water or other aqueous diluent means thereconstituted lyophilized powder is stable in solution for about 48hours or more at room temperature and ambient light conditions. Oneadvantage of the stability of the lyophilized powder is extendedpharmaceutical product shelf life. Extended pharmaceutical shelf lifeoffers significant economic advantages.

In yet another embodiment, the present invention discloses stablepharmaceutical formulations comprising temozolomide and at least onedissolution enhancing agent sufficient to substantially dissolvetemozolomide in at least one aqueous diluent. The dissolution enhancingagent can be urea, L-histidine, L-threonine, L-asparagine, L-serine,L-glutamine, or mixtures thereof. The pharmaceutical formulationcomprising Temozolomide may have at least one other ingredient such as,for example, a bulking agent, buffer or pH adjuster, which are describedabove both as to their nature and amounts. Such pharmaceuticalformulations can have the stability as discussed above. The inventionadditionally describes a process of preparing such stable pharmaceuticalformulations.

In a further embodiment, the above-described formulations comprisingTemozolomide can be lyophilized into a lyophilized powder and stored ina suitable container or such article of manufacture in a conditionsuitable to be reconstituted later at an appropriate time in water orother aqueous diluent(s) for administration to a patient in need oftreatment as described above. The lyophilized powders can have long termstorage stability as discussed above.

The stable pharmaceutical formulations and lyophilized forms comprisingTemozolomide are described in more detail in the EXAMPLES section below.

The invention is therefore advantageous in that it allows the formationof a stable aqueous solution containing an antineoplastic agent. Otheradvantages include the ability of the pharmaceutical formulation to belyophilized and stored as a lyophilized powder suitable to bereconstituted as an aqueous solution, which solution is suitable to beadministered to a patient in need thereof.

The term “aseptic” means preventing microbial contamination.

The term “aqueous diluent(s)” means aqueous fluids suitable forinjection into a patient. Non-limiting examples of aqueous diluentsinclude water, normal saline, 5% dextrose solution, and other fluidssuitable for injection into a patient, preferably suitable forintravenous injection into a patient.

Pharmaceutically acceptable salts suitable as acid addition salts aswell as salts providing the anion of the quaternary salt include thoseprepared from acids such as hydrochloric, hydrobromic, phosphoric,sulfuric, maleic, citric, acetic, tartaric, succinic, oxalic, malic,glutamic, pamoic and the like, and other acids related to thepharmaceutically acceptable salts listed in Journal of PharmaceuticalScience, 66, 2 (1977).

The term “therapeutically effective amount” shall mean that amount ofactive ingredient that will elicit the biological or medical response ofa tissue, system or animal that is being sought by a researcher orclinician.

The term “extended pharmaceutical shelf life” is intended to mean ashelf life for pharmaceutical products from about 12 months to about 18months wherein there is a loss of no greater than 10% of the activeagent when stored at recommended storage conditions. The active agentfor this is invention is intended to mean the antineoplastic agent.

The term “patient” is intended to mean animals, mammals, humans,monkeys, rodents, domestic and farm animals.

The term “therapeutically effective amount” is intended to mean anamount of a therapeutic agent of the composition, such as temozolomideor other antineoplastic agents described above, that will have anantineoplastic effect on a tissue, system, animal or mammal that isbeing sought by the administrator (such as a researcher, doctor orveterinarian), which includes alleviation of the symptoms of thecondition or disease being treated and the prevention, slowing orhalting of progression of the neoplastic condition.

The term “weight percent” (“wt %”) for purposes of this invention iscalculated on a basis of total weight of the pharmaceutical formulation.

The term “Temozolomide” is intended to mean a compound having theformula:

The synthesis of Temozolomide is well known. See, for example, Stevenset al., J. Med. Chem, 27, 196-201 (1984), and Wang et al., J. Chem.Soc., Chem. Commun., 1687-1688 (1994) which are incorporated herein byreference.

EXAMPLES

The following examples have been set forth below as a guide to thepractitioner and are not meant in any way to limit the scope of thepresent invention.

Example 1: The Pharmaceutical Formulation of the Invention is GenerallyPrepared by the Following Procedure

1. Urea or an amino acid with Polysorbate a bulking agent, and a buffer,is charged and dissolved in at least one aqueous diluent, wherein theamino acid is L-histidine, L-threonine, L-asparagine, L-serine,L-glutamine or mixtures thereof.2. An antineoplastic agent is charged and dissolved into the solutionfrom step 1. Dissolution of the antineoplastic agent is completed bymixing.3. Water is added to the solution from step 2 to bring the batch to avolume with a desired solution density.4. The solution from step 3 is aseptically filtered.

Example 2:*for Batches A-D in Examples 2-5, the Actual Amount ofTemozolomide to be Charged is Adjusted According to the Purity of theDrug Substance Batch Using the Following Formula

grams Temozolomide=2.50×100/% Purity.

Sample Calculation:

Temozolomide drug substance=97.0% pure.2.50×100/97.0=2.58 grams of Temozolomide to be charged for a 1-Literbatch.**For batches A-D in Examples 2-5, grams of concentrated HydrochloricAcid (HCl) to be charged will be calculated as follows:

grams of concentrated HCL=100×(grams of HCl required)/% w/w ConcentratedHCl

Sample Calculation: Concentrated HCl=38.0% w/w

100×1.48/38.0=3.895 grams Concentrated HCl1 L of Batch A was prepared by the procedure described below.

Batch A Ingredients mg/ml wt % *Temozolomide 2.50 8 L-Threonine 4.00 13Polysorbate 80 3.00 9 Sodium Citrate Dihydrate 5.88 19 Mannitol 15.0 48**Hydrochloric acid 1.48 5 Water for injection qs ad 1.00 ml

Process of Manufacturing 1-Liter of Batch a Prior to Lyophilization:

1. 4.00 g of L-Threonine, 3.00 g of polysorbate 80, 15 g of mannitol,5.88 g of sodium citrate dihydrate, and 1.48 g of Hydrochloric acid, inthat order, were charged and dissolved in water with agitation. Theamount of water was about 80% of the total volume (batch volume).2.*2.58 g of Temozolomide was charged and dissolved with agitation intothe solution from Step 1. Complete dissolution of Temozolomide mayrequire up to 2 hours of mixing.3.**Water is added to bring the batch to the final volume with asolution density of 1.008±0.002 g/mL at 25° C. The solution was mixedfor at least 15 minutes.4. The solution was aseptically filtered through a sterilized 0.22 μmfilter (Millipore, GVWP, Durapore), which was washed and tested forintegrity, into a sterilized, stainless steel pressure vessel orequivalent. For a batch of 10 liters or less, a 293-mm membrane filteror equivalent was used. For batch sizes greater than 10 Liters, a 0.22μm cartridge filter (MCGL40S Millidisk, Durapore GVWP) was used.

The compounded batch can be stored at room temperature (19-25° C.) forup to 8 hours in a sealed, sterilized, stainless steel pressure vessel,and then refiltered following storage.

5. The solution from step 4 was aseptically filled into 20-mL Type 1flint glass vials in aliquots of 10.7±0.2 mL. The vials were washed andsterilized prior to being filled.6. 20-mm Daikyo D-713 lyo-shape rubber stoppers, which were washed,siliconized and sterilized, were aseptically inserted into the glassvials from step 5 in the lyophilization position.

Example 3: 1 L of Batch B was Prepared by the Procedure Described AboveExcept that 2 g of L-Histidine was Used Instead of 4.00 g ofL-Threonine, and 2.08 g of Hydrochloric Acid was Used Instead of 1.48 gof Hydrochloric Acid in Step 1

Batch B Ingredients mg/ml wt % *Temozolomide 2.50 8% L-Histidine 2.00 7%Polysorbate 80 3.00 10% Sodium Citrate dihydrate 5.88 19% Mannitol 15.049 **Hydrochloric acid 2.08 7 Water for injection qs ad 1.00 ml

Example 4: 1 L of Batch C was Prepared by the Procedure Described AboveExcept that 4 g of L-Asparagine was Used Instead of 4.00 g ofL-Threonine in Step 1

Batch C mg/ml (except for Ingredients water) wt % *Temozolomide 2.50 8L-Asparagine 4.00 13 Polysorbate 80 3.00 9 Sodium Citrate dihydrate 5.8819 Mannitol 15.0 48 **Hydrochloric acid 1.48 5 Water for injection qs ad1.00 ml

Example 5: 1 L of Batch D was Prepared by the Procedure Described AboveExcept that 5 g of Urea was Used Instead of 4.00 g of L-Threonine and3.00 g of Polysorbate 80 in Step 1

Batch D Ingredients mg/ml wt % *Temozolomide 2.50 9 Urea 5.00 17 SodiumCitrate dihydrate 5.88 20 Mannitol 15.0 51 **Hydrochloric acid 1.48 5Water for injection qs ad 1.00 ml

After lyophilization of batches A-D, the resulting powder was storedand, over a period of one week, four weeks, eight weeks and twelveweeks, the samples were reconstituted with water for analysis. Theresults are present in Table 1 below.

TABLE 1 Stability % Initial % Initial Mean % Initial MoistureReconstitution Batch # Time Point/Condition Assay 1 Assay 2 (n = 2) (%)Ph Time (sec) A Initial 100.00 100.00 100.00 0.4 3.75 30 A 1 week,LTC/LTR 100.00 99.63 99.82 0.4 3.77 30 A 1 week, LTC/LTR Control 100.1199.99 100.05 0.4 3.77 30 A 4 week, 4 100.18 99.62 99.9 0.4 3.83 30 A 4week, 25H 100.24 99.13 99.69 0.3 3.84 30 A 4 week, 40 99.17 98.11 98.640.4 3.84 30 A 8 week, 25H 99.43 98.82 99.125 0.4 3.81 30 A 12 week, 499.37 99.59 99.48 0.3 3.83 30 A 12 week, 25H 99.24 99.22 99.23 0.4 3.8230 B Initial 100.00 100.00 100.00 1.6 3.96 30 B 1 week, LTC/LTR 100.65100.41 100.53 1.3 6.97 30 B 1 week, LTC/LTR Control 99.63 100.27 99.951.6 3.97 30 B 4 week, 4 100.45 100.43 100.44 2.1 4.00 30 B 4 week, 25H99.89 99.04 99.47 2.0 4.00 30 B 4 week, 40 99.86 99.66 99.76 2.0 4.00 30B 8 week, 25H 99.91 100.15 100.03 2.0 4.04 30 B 12 week, 4 100.16 100.00100.08 2.0 4.01 30 B 12 week, 25H 98.84 100.2 99.52 2.0 4.00 30 CInitial 100.00 100.00 100.00 0.3 4.00 30 C 1 week, LTC/LTR 97.59 103.68100.635 0.4 4.04 30 C 1 week, LTC/LTR Control 98.14 99.55 98.845 0.54.04 30 C 4 week, 4 97.09 97.47 97.28 0.4 4.03 30 C 4 week, 25H 98.4997.18 97.835 0.5 4.03 30 C 4 week, 40 97.96 97.28 97.62 0.6 4.06 90 C 8week, 25H 98.42 97.56 97.99 0.6 4.04 30 C 12 week, 4 98.27 96.94 97.6050.4 4.02 30 C 12 week, 25H 98.67 97.77 98.22 0.6 4.02 30 D Initial100.00 100.00 100.00 0.4 4 30 D 1 week, LTC/LTR 103.87 98.41 101.14 0.34.03 30 D 1 week, LTC/LTR Control 100.46 98.95 99.705 0.4 4.02 30 D 4week, 4 101.06 99.3 100.18 0.4 4.02 30 D 4 week, 25H 101.69 98.97 100.330.4 4.02 30 D 4 week, 40 101.49 98.95 100.22 0.7 4.03 30 D 8 week, 25H100.86 98.78 99.82 0.5 4.01 30 D 12 week, 4 101.3 99.28 100.29 0.4 4 30D 12 week, 25H 101.37 98.59 99.98 0.5 4 30

The results show that the temozolomide in batches A-D was stable overone, four, eight and twelve week periods.

Example 6: Procedure for Lyophilization

The 20-mL glass vials from Examples 2-5, which were filled with thesolution from one of Batches A-D, were placed into trays prior tolyophilization. Lyophilization was then carried out by the followingprocedure. A Lyostar Lyophilizer, which is manufactured by FTS systems,was used for the lyophilization.

1. Lyophilizer shelves were cooled to −50±5° C.2. The trays of filled vials were aseptically loaded onto thelyophilizer shelves.3. The lyophilizer shelves were held at a temperature of about 50±5° C.for 4.5 hours.4. The lyophilizer shelves were warmed to about −22±2° C. in 1.5 hoursand the product was maintained at a temperature of about −22±2° C. forat least 6 hours.5. The shelves were cooled to about −50° C. in 3 hours and held at about−50±5° C. for 3 hours.6. The condenser temperature was lowered to about −45° C. or below, andthen the chamber was evacuated to about 100 μm Hg.7. Once the chamber reached 100 μm Hg pressure, full vacuum (50-70 μMHg) was applied and held for about 2 hours with the shelf temperature atabout −50±5° C.8. The pressure was changed to about 150 μm Hg and held for 30 minutes.9. The shelves were heated to about 5° C. in 1 hour and 45 minutes. Theshelf temperature was then maintained at about 5° C. for about 6 hoursat approximately 150 μm Hg pressure.10. The shelves were cooled to −2° C. in about 3 hours and the shelftemperature was maintained at about −2±2° C. for 32 hours atapproximately 150 μm Hg pressure.11. The shelves were heated to about 45° C. in 8 hours and maintained ata temperature of about 45±2° C. for about 5 hours at about 150 μm Hgpressure. The product temperature was then kept above −10° C.12. The shelves were cooled to about 4° C. at a chamber pressure ofabout 150 μm and maintained at about 4° C. for a minimum of about 1hour.13. The chamber was vented with sterile filtered nitrogen to about 933mBar.14. The vials were stoppered inside the lyophilizer.15. The chamber was vented with sterile filtered nitrogen to atmosphericpressure.16. The vials were removed from the lyophilizer and crimped with 20-mmaluminum seals.17. The vials were stored at about 2° to about 8° C. until inspectionwas completed.

It will be appreciated by those skilled in the art that changes could bemade to the embodiments described above, including chemical andstereochemical changes, without departing from the broad inventiveconcept thereof. It is understood, therefore, that this invention is notlimited to the particular embodiments disclosed, but it is intended tocover modifications which are within the spirit and scope of theinvention, as defined by the appended claims.

What is claimed is:
 1. A process of making a pharmaceutical formulationcomprising the steps of: (i) dissolving at least one dissolutionenhancing agent in at least one aqueous diluent wherein said dissolutionenhancing agent is selected from the group consisting of urea,L-histidine, L-threonine, L-asparagine, L-serine, and L-glutamine; and(ii) adding at least one antineoplastic agent or a pharmaceuticallyacceptable salt thereof.
 2. The process according to claim 1 furthercomprising: a) adding at least one bulking agent; b) adding at least onebuffer; c) adding at least one pH adjuster to form a solution; and d)filtering said solution.
 3. The process according to claim 2, furthercomprising lyophilizing said solution from step (d) to form alyophilized powder.
 4. The lyophilized powder, produced by the processof claim
 3. 5. An article of manufacture comprising a containercontaining the lyophilized powder of claim
 4. 6. The article ofmanufacture according to claim 5, wherein said container is a syringe orvial.
 7. The article of manufacture according to claim 5, furthercomprising a volume of at least one aqueous diluent suitable forreconstitution of said lyophilized powder.
 8. A pharmaceuticalformulation suitable for administration to a patient, said formulationprepared by reconstituting the lyophilized powder of claim 4 in a volumeof at least one aqueous diluent.
 9. A process for treating or preventingdisease in a patient comprising administering a therapeuticallyeffective amount of the pharmaceutical formulation comprisingTemozolomide or a pharmaceutically acceptable salt thereof, at least oneaqueous diluent, and at least one dissolution enhancing agent sufficientto substantially dissolve said Temozolomide, wherein said dissolutionenhancing agent is selected from the group consisting of urea,L-histidine, L-threonine, L-asparagine, L-serine, and L-glutamine, to apatient in need thereof.
 10. The process for treating or preventingdisease according to claim 9, wherein said disease is carcinoma,sarcoma, melanoma, glioma, glioblastoma, brain cancer, lung cancer,thyroid follicular cancer, pancreatic cancer, breast cancer, bladdercancer, myelodysplasia, prostate cancer, testicular cancer, anaplasticastrocytoma, colon and rectal cancer, lymphoma, leukemia, or mycosisfungoides.
 11. The process for treating or preventing disease accordingto claim 9, wherein said patient is an animal.
 12. The process fortreating or preventing disease according to claim 9, wherein saidpatient is a mammal.
 13. The process for treating or preventing diseaseaccording to claim 9, wherein said patient is a human.
 14. A process fortreating or preventing disease in a patient comprising administering atherapeutically effective amount of the pharmaceutical formulation ofclaim 8 to a patient in need thereof.
 15. The process for treating orpreventing disease according to claim 14, wherein said disease iscarcinoma, sarcoma, melanoma, glioma, glioblastoma, brain cancer, lungcancer, thyroid follicular cancer, pancreatic cancer, breast cancer,bladder cancer, myelodysplasia, prostate cancer, testicular cancer,anaplastic astrocytoma, colon and rectal cancer, lymphoma, leukemia, ormycosis fungoides.
 16. The process for treating or preventing diseaseaccording to claim 14, wherein said patient is an animal.
 17. Theprocess for treating or preventing disease according to claim 14,wherein said patient is a mammal.
 18. The process for treating orpreventing disease according to claim 14, wherein said patient is ahuman.